In the past decade, cell and gene therapies have debuted successfully for various therapeutic areas and are no longer restricted to academic research trials. Therefore, building a cell and gene therapy company would require strategic and organizational capabilities that are slightly different from the conventional pharmaceutical landscape.

At the Reuters Events Cell & Gene Therapy Conference, several eminent speakers shared their views on what companies must consider while commercializing cell and gene therapies.

The session titled ‘Build and standardize an agile commercialization network’ was moderated by GeneOnline’s senior editor, Rajaneesh K. Gopinath. The panel consisted of the following experts.

Christine Strobele, Senior Director, US Launch lead- darvadstrocel at Takeda Sandra Anderson, Senior VP, Commercialization, and Strategy, Innomar Strategies Rita Johnson-Greene, VP Sales and Qualified Treatment Centers, bluebird bio Bethany Rogers,  VP Marketing- tabelecleucel, Atara Biotherapeutics